Crippa, Jose AlexandreCrippa, Ana C.S.Hallak, Jaime E. C.Martín-Santos Laffon, RocíoZuardi, Antonio W.2020-03-052020-03-052016-09-301663-9812https://hdl.handle.net/2445/152137Animal studies and preliminary clinical trials have shown that cannabidiol (CBD)-enriched extracts may have beneficial effects for children with treatment-resistant epilepsy. However, these compounds are not yet registered as medicines by regulatory agencies. We describe the cases of two children with treatment-resistant epilepsy (Case A with left frontal dysplasia and Case B with Dravet Syndrome) with initial symptom improvement after the introduction of CBD extracts followed by seizure worsening after a short time. The children presented typical signs of intoxication by Δ9-THC (inappropriate laughter, ataxia, reduced attention, and eye redness) after using a CBD-enriched extract. The extract was replaced by the same dose of purified CBD with no Δ9-THC in both cases, which led to improvement in intoxication signs and seizure remission. These cases support pre-clinical and preliminary clinical evidence suggesting that CBD may be effective for some patients with epilepsy. Moreover, the cases highlight the need for randomized clinical trials using high-quality and reliable substances to ascertain the safety and efficacy of cannabinoids as medicines.6 p.application/pdfengcc-by (c) Crippa, Jose Alexandre et al., 2016http://creativecommons.org/licenses/by/3.0/esCànnabisEpilèpsia en els infantsModels animals en la investigacióCannabisEpilepsy in childrenAnimal models in researchinfo:eu-repo/semantics/article6700302020-03-05info:eu-repo/semantics/openAccess27746737